Ice Bear Therapeutics SPC is pioneering a biotherapeutic manufacturing platform that leverages advanced mammalian cell line technology to produce biotherapeutics more efficiently and cost-effectively. The company focuses on continuous manufacturing processes, which allow for faster production times and reduced costs, making it possible to meet the growing global demand for biosimilar drugs. Their initial product candidates are biosimilar insulins, specifically Glargine and Lispro, aimed at addressing the needs of the 451 million patients with diabetes worldwide. This strategic focus is driven by the increasing prevalence of diabetes, the rising demand for biosimilars, and a favorable regulatory environment that supports quicker FDA approvals for these products.

By utilizing their innovative manufacturing approach, Ice Bear Therapeutics aims to disrupt the traditional, risk-heavy centralized manufacturing model that currently dominates the biotherapeutics market. The company is actively seeking partnerships and investments to further their mission of making biosimilar insulins accessible to all patients globally. Their commitment to low-cost and rapid manufacturing processes positions them to capitalize on the significant market opportunity presented by the growing need for affordable insulin options.

United States

Ice Bear Therapeutics SPC is a social purpose company based in Seattle, WA, founded 2021, with the mission of bringing affordable insulin to patients with type 1 or type 2 diabetes.

Ice Bear Therapeutics

Company Details